Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study
The Lancet Oncology Sep 07, 2017
van Zandwijk N, et al. – The safety, optimal dosing, and activity of TargomiRs were investigated in patients with malignant pleural mesothelioma. Findings suggested the acceptable safety profile and early signs of activity of TargomiRs in these patients. In light of this outcome, experts supported additional studies of TargomiRs in combination with chemotherapy or immune checkpoint inhibitors.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
